Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke.
Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY x 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.
Lutsep
Helmi L
HL
Oregon Stroke Center, Oregon Health & Science University, Portland, OR 97239, USA. lutseph@ohsu.edu
D000208:Acute Disease; D000368:Aged; D001578:Benzopyrans / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome
D001578:Benzopyrans; D018696:Neuroprotective Agents; D017366:Serotonin Receptor Agonists; D013844:Thiazoles; C111221:repinotan hydrochloride